Macmillan: Review of drug information

Macmillan: Review of drug information

BOPA Members – Help required!

Macmillan produces many cancer drug treatment pages. They are widely used by healthcare professionals and people affected by cancer across the UK. We work hard to ensure that they provide the information people need to understand their treatment and ask questions. These online pages also link to other sources of information and support about cancer types, types of treatments, and managing side effects. The information needs to be current, clinically accurate and reflect the real-world patient experience.  We rely on expert speciality pharmacists to review our drug information, and make suggestions, to ensure we have met our goal.

We are always looking for specialist oncology and haematology pharmacists to join our review panel. We ask that our reviewers complete a short survey so that we can capture contact details, specialities and interests in a way that is GDPR compliant. We have a protected database to keep these details secure.

The help can range from looking at a couple of pages once or twice a year, or more if you are able. We are always flexible, you can always say “I am not able to this time” or “yes I can review, if you can give me more time”. We always appreciate that people are kindly giving us their time and expertise and we are very grateful.

We send the pages as Word documents. We ask if you could add comments and/or mark any changes using the ‘Track changes’ facility. Or you may prefer to email us with your comments.
We are generally looking for:

  • Is the information clinically accurate and up-to-date?
  • Are there any issues that you feel we have left out?
  • Is there anything that you think could have been explained more clearly?
  • Feel free to add any other comments that you have.

If you would like to join our professional reviewers or would like to find out more please contact Helen Purdon at [email protected]

Thank you for your ongoing help,
Best wishes,
Helen

Helen Purdon (She/her)
Cancer Information Development Nurse

The below pages are to be reviewed soon:

  • Stilboestrol
  • Palbociclib
  • Ribociclib
  • Doxorubicin
  • Doxorubicin and ifosfamide
  • Gefitinib
  • Midostaurin
  • De Gramont/modified de Gramont
  • Cisplatin and 5FU
  • Leuprorelin
  • CODOX-M
  • Torifemine
  • GemCarbo
  • Crizotinib
  • Rasburicase
  • EPO
  • G-CSF
  • Cabazitaxel
  • TC
  • CVP
  • Bendamustine
  • Encorafenib and binimetinib
  • Mesna

Latest News

By BOPA Committee on behalf of UK SACT board on 23rd May 2025

UK SACT Board publication: Guidance on the contents of a SACT protocol

  Dear Colleague,   Please find a link to the updated publication, “Guidance for the Content of SACT Protocol,” available here: https://www.uksactboard.org/publications.   This document has been developed to support…

Read article
By BOPA Executive Committee on 21st May 2025

Vision and Common Purpose for UK Pharmacy Professional Leadership – UKPPL Board and BOPA

BOPA is an Ex-Officio Member (Specialist Pharmacy Group) of the UKPPL Board with our Chair, Joseph Williams, representing BOPA members and all Cancer Pharmacy Professionals.  Through the Board’s work, closer…

Read article
By BOPA Executive Committee on 14th May 2025

BOPA Fellowship Nominations are NOW OPEN!

We are pleased to announce that BOPA Fellowship Nominations have now opened for 2025.  There is a clear nomination and selection process including specific criteria for assessing the nominated individuals.…

Read article
By BOPA Committee on 13th May 2025

#BOPA2025 at ICC Belfast – Draft Agenda now available

The 28th British Oncology Pharmacy Association (BOPA) Annual Conference, 3-5 October 2025, ICC Belfast The Draft Agenda is available to view here: https://www.bopa.org.uk/resources/the-28th-bopa-annual-conference-2025-draft-agenda/ The conference will include an exciting variety…

Read article